Skip to main content
Michael Brenner, MD, Rheumatology, Boston, MA

Michael B Brenner MD


E. F. Brigham Professor of Medicine, Brigham and Women's Hospital, Harvard Medical School

Join to view full profile
  • Brigham And Women's Hospital Rheumatology Immunology &60 Fenwood Rd. Rm 6002UBoston, MA 02115

  • Phone+1 617-525-1000

Dr. Brenner is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Rheumatology, 1979 - 1982
  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Internal Medicine, 1975 - 1979
  • Vanderbilt University School of Medicine
    Vanderbilt University School of MedicineClass of 1975

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1979 - Present
  • MA State Medical License
    MA State Medical License 1985 - 2027

Awards, Honors, & Recognition

  • Fellow (FACR) American College of Rheumatology

Publications & Presentations

PubMed

Journal Articles

  • Metabolic Reprogramming of Natural Killer Cells in Obesity Limits Antitumor Responses  
    Ali Tavakkoli, Michael B Brenner, Kevin Wei, Ashley Vernon, Nature
  • Plateletpheresis-Associated Lymphopenia in Frequent Platelet Donors  
    Michael B Brenner, A Helena Jonsson, Dan L Longo, Deepak A Rao, Richard M Kaufman, Nancy Berliner, Duane R Wesemann, Blood
  • High-Throughput Identification of Noncoding Functional SNPs via Type IIS Enzyme Restriction  
    Soumya Raychaudhuri, Jing Cui, Michael B Brenner, Peter A Nigrovic, Nature

Press Mentions

  • Newborn Bio Business Mestag Therapeutics Raises $11m Seed Cash
    Newborn Bio Business Mestag Therapeutics Raises $11m Seed CashApril 26th, 2021
  • Mestag Therapeutics Launches with Seed Financing of $11 Million to Develop Therapeutics Targeting Activated Fibroblast Populations Across Inflammatory Disease and Cancer
    Mestag Therapeutics Launches with Seed Financing of $11 Million to Develop Therapeutics Targeting Activated Fibroblast Populations Across Inflammatory Disease and CancerApril 20th, 2021
  • U.S. Department of Defense Awards $3.3 Million Grant to Alivio Therapeutics
    U.S. Department of Defense Awards $3.3 Million Grant to Alivio TherapeuticsSeptember 12th, 2018

Grant Support

  • Cellular cross-talk in autoimmune diseaseBRIGHAM AND WOMEN'S HOSPITAL2021–2031
  • Immunologic Mechanisms and Rheumatic DiseasesBRIGHAM AND WOMEN'S HOSPITAL1985–2030
  • CD8 T cell derived Granzyme K activates complement that drives synovial fibroblast inflammationBRIGHAM AND WOMEN'S HOSPITAL2023–2028
  • Single cell and spatial genomic analyses of specimens from patients with autoimmune diseases (Technology Core)BRIGHAM AND WOMEN'S HOSPITAL2022–2026
  • Expanded fibroblast subset drives pathology in rheumatoid arthritisBRIGHAM AND WOMEN'S HOSPITAL2015–2026

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: